Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
European Urology|September 10, 2013
Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancerAndres Jan Schrader, Sandra Seseke, Christian Keil, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2015
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studiesLaurence Albiges, Ulrich Kube, Jean-Christophe Eymard, et al.
Leukemia & Lymphoma|July 7, 2007
The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell linesKai Uwe Chow, Daniel Nowak, Bettina Trepohl, et al.
Oncology Research and Treatment|January 21, 2019
Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO StudyPeter J Goebell, Edwin Hermann, Ulrich Kube, et al.
The Oncologist|December 2, 2015
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseIordanis Gravanis, Kyriaki Tzogani, Paula van Hennik, et al.
Urologia Internationalis|February 4, 2024
Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature ReviewAnnemarie Uhlig, Lothar Bergmann, Martin Bögemann, et al.
BMC Cancer|May 1, 2015
Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional studyLothar Bergmann, Ulrich Kube, Christian Doehn, et al.
Future Oncology (London, England)|September 23, 2020
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinomaPeter J Goebell, Philipp Ivanyi, Jens Bedke, et al.
Onkologie|March 15, 2013
Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional studyLothar Bergmann, Peter J Goebell, Ulrich Kube, et al.
Oncology Research and Treatment|April 2, 2014
Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practiceLothar Bergmann, Jochaim Beck, Kathrin Bothe, et al.
Pageof 6